Avoiding psychotropic drug interactions in the cardiovascular patient.
Recent advances in our understanding of the hepatic cytochrome P450 inhibitory effects of the newer antidepressants have increased concern about drug interactions in the practice of psychiatry. The authors summarize the potential interactions of psychoactive drugs with cardiovascular medications. Practicing psychiatrists encounter many patients with cardiovascular disease, and an awareness of these interactions will improve knowledgeable prescribing for medically ill patients with comorbid mental disorders.
DeVane
C L
CL
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston 49425, USA.
Markowitz
J S
JS
D002317:Cardiovascular Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D005569:Formularies as Topic; D006801:Humans; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy*; D011570:Psychiatry; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014481:United States
D002317:Cardiovascular Agents; D011619:Psychotropic Drugs; D003577:Cytochrome P-450 Enzyme System